The expression of a disintegrin and metalloproteinase with thrombospondin motifs 4 in human macrophages is inhibited by the anti-atherogenic cytokine transforming growth factor-β and requires Smads, p38 mitogen-activated protein kinase and c-Jun

Int J Biochem Cell Biol. 2011 May;43(5):805-11. doi: 10.1016/j.biocel.2011.02.005. Epub 2011 Feb 18.

Abstract

Atherosclerosis is an inflammatory disorder of the vasculature that is orchestrated by the action of cytokines. Macrophages play a prominent role in all stages of this disease, including foam cell formation, production of reactive oxygen species, modulation of the inflammatory response and the regulation of the stability of atherosclerotic plaques. The role of the matrix metalloproteinase family in the control of plaque stability is well established. A disintegrin and metalloproteinase with thrombospondin motif (ADAMTS) family has been implicated in several diseases and the expression of ADAMTS-4 in macrophages of atherosclerotic lesions has suggested a potential role for this protease in atherosclerosis. However, the action of cytokines on the expression of ADAMTS-4 in macrophages is poorly understood. We have investigated here the effect of transforming growth factor-β (TGF-β) on ADAMTS-4 expression in macrophages along with the regulatory mechanisms underlying its actions. Consistent with the anti-atherogenic role of TGF-β, this cytokine decreased the expression of ADAMTS-4 mRNA and protein in human macrophages. Transient transfection assays showed that the -100 to +10 promoter region contained the minimal TGF-β response elements. Small-interfering RNA-mediated knockdown revealed a critical role for Smads, p38 mitogen-activated protein kinase and c-Jun in the action of TGF-β on ADAMTS-4 mRNA expression. These studies show for the first time that TGF-β inhibits the expression of ADAMTS-4 in human macrophages and identifies the signalling pathways underlying this response. The inhibition of macrophage ADAMTS-4 expression is likely to contribute to the anti-atherogenic, plaque stabilisation action of TGF-β.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM Proteins / genetics
  • ADAM Proteins / metabolism*
  • ADAMTS4 Protein
  • Atherosclerosis / drug therapy
  • Atherosclerosis / metabolism
  • Cell Line, Tumor
  • Down-Regulation / drug effects
  • Gene Expression Regulation, Enzymologic / drug effects*
  • Humans
  • JNK Mitogen-Activated Protein Kinases / metabolism*
  • Macrophages / drug effects*
  • Macrophages / metabolism
  • Procollagen N-Endopeptidase / genetics
  • Procollagen N-Endopeptidase / metabolism*
  • Promoter Regions, Genetic / genetics
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Smad Proteins / metabolism*
  • Transforming Growth Factor beta1 / pharmacology*
  • Transforming Growth Factor beta1 / therapeutic use
  • p38 Mitogen-Activated Protein Kinases / metabolism*

Substances

  • RNA, Messenger
  • Smad Proteins
  • Transforming Growth Factor beta1
  • JNK Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • ADAM Proteins
  • Procollagen N-Endopeptidase
  • ADAMTS4 Protein
  • ADAMTS4 protein, human